Molecular Targeted Therapies for Patients with Metastatic Renal Cell Cancer
- *Corresponding Author:
- Takeshi Yuasa
Department of Urology and Medical Oncology
Cancer Institute Hospital
Japanese Foundation for Cancer Research
Tokyo, 138-8550, Japan
E-mail: [email protected]
Received Date: January 25, 2012; Accepted Date: February 01, 2012; Published Date: February 03, 2012
Citation: Yuasa T, Fujii Y, Takahashi S, Fukui I, Yonese J (2012) Molecular Targeted Therapies for Patients with Metastatic Renal Cell Cancer. Translational Medic S2:003. doi:10.4172/2161-1025.S2-003
Copyright: © 2012 Yuasa T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Major breakthroughs have occurred recently in the knowledge of the genetics and transduction pathways involved in various malignancies, including renal cell cancer (RCC). Novel targeted therapies directed against angiogenesis and the mammalian target of rapamycin (mTOR) pathway is now being developed for the treatment of metastatic RCC. Currently, four anti-angiogenesis agents, (sorafenib, sunitinib, bevacizumab, pazopanib) and two specific inhibitors of the mTOR kinase (temsirolimus and everolimus) are approved by the United States Food and Drug Administration. Moreover, at least three other tyrosine kinase inhibitors (TKI) (axitinib from Pfizer, tivozanib from AVEO Pharmaceuticals, and dovitinib from Novartis) are in advanced stages of clinical trials. Here, we will discuss the molecular targeted agents for RCC patients in clinical trials as well as in clinical practice.